Overview

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the safety, antiviral and anti-TNF-alpha activity, and preliminary efficacy of thalidomide in reducing weight loss in patients with HIV wasting syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Celgene Corporation

Treatments:

Thalidomide